Drug discovery is evolving fast, and the challenges are growing just as quickly. From our conversations with biotechs and pharma teams, we know the barrier isn’t ambition, it’s connection.
When work passes between separate disciplines or locations, insights slow, risks rise, and timelines drift.
Our collaboration with STORM Therapeutics shows what’s possible when those gaps are removed.The Result
By uniting chemistry, biology, structural science, DMPK and in vivo expertise early, the programme progressed from lead to pre‑candidate nomination in just 18 months against a two‑year target, in an area where four‑year timelines are typical.
This wasn’t driven by one technology or discipline.
It was driven by connection: co‑located teams, real‑time decisions, and shared scientific ownership.
Three Key Takeaways
- Connected teams move faster and deliver more effectively than siloed functions.
- Real‑time data flow supports faster, more confident decision‑making and clearer prioritisation.
- Flexible, collaborative scientific dialogue helps identify and resolve challenges earlier.
Whether you're optimising an existing hit series or exploring a new target class, the way teams communicate and collaborate can make or break your timelines.
This case study highlights what becomes possible when structure, partnership and science align.
What’s Inside
- How multidisciplinary teams worked as a seamless extension of STORM’s in‑house scientists
- The scientific strategy behind progressing a best‑in‑class DHX9 inhibitor
- How rapid iteration and diverse hit‑finding approaches accelerated momentum
- The decisions, data flow, and collaboration framework that enabled early clarity and reduced risk
Hear From the STORM Team:
“It has been a pleasure to work with the Sygnature team on our best‑in‑class inhibitor project. From project start, the multidisciplinary team at Sygnature functioned as an extension of our in‑house team… They responded fearlessly to our ambitious timelines and collaborated closely to allow us to achieve preclinical candidate compound nomination within a really impressive timeframe.”
- Taran Khanam, Biology Lead and Principal Scientist, STORM Therapeutics
It has been a pleasure to work with the Sygnature team on our best-in-class inhibitor project. From project start, the multidisciplinary team at Sygnature functioned as an extension of our in-house team, providing additional expertise across the drug discovery process; particularly in protein sciences, computational and synthetic chemistry and in vivo biology. They responded fearlessly to our ambitious timelines and collaborated closely to allow us to achieve preclinical candidate compound nomination within a really impressive timeframe. I wouldn’t hesitate to work with the Sygnature team again.
- Helen Harrison, Director of Discovery Biology, STORM Therapeutics